Talazoparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Talazoparib (coding:ncit:C95733)

RxNorm: talazoparib (coding:rxcui:2099704, coding:omop:35201068)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) RAD51B oncogenic variants Prostate Adenocarcinoma Talazoparib
EMA (1) FDA (2) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
EMA (1) FDA (2) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
FDA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) ATM pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) ATM oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) ATR oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) CDK12 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) ATR pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) FANCA oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) CHEK2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) CHEK2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) FANCA pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) MLH1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) PALB2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) PALB2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) MLH1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) MRE11 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) RAD51C pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) RAD51C oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) MRE11 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) NBN oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) NBN pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) CDK12 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib